Kura Oncology, Inc. (NASDAQ:KURA) Receives $28.83 Average Price Target from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $28.83.

A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. StockNews.com upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a report on Wednesday. Finally, Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd.

Institutional Trading of Kura Oncology

Hedge funds have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in shares of Kura Oncology in the 3rd quarter worth approximately $25,000. ProShare Advisors LLC increased its position in shares of Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC lifted its holdings in shares of Kura Oncology by 2.4% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after purchasing an additional 1,673 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC grew its stake in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after buying an additional 2,167 shares during the last quarter.

Kura Oncology Trading Down 3.5 %

Shares of KURA opened at $15.92 on Friday. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -6.75 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1-year low of $8.80 and a 1-year high of $24.17. The company has a 50-day moving average of $18.50 and a 200 day moving average of $19.92.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.